A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.
The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer
Primary Sponsor
Trans-Tasman Radiation Oncology Group (TROG)
Final Accrual
60
Trial Chairperson
Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC
Clinical Trial Registration
Related Post
21 April, 2025
Trial data-sharing made easier with HeSANDA initiative
Latest News: 21 April 2025 TROG Cancer Research is
16 April, 2025
Mark Hughes Foundation grant for innovative SMART trial into brain metastases
LATEST NEWS: 15 April 2025 An innovative trial aimed
